Chinese Journal of Chromatography ›› 2026, Vol. 44 ›› Issue (9): 1028-1037.DOI: 10.3724/SP.J.1123.2025.08014
• Articles • Previous Articles Next Articles
ZHANG Xiaonan1,2, MA Zhichao1,2, LIU An1, HUANG Yuan3,*(
), MIN Xuehong1,2, LIU Mei2, XIE Zhengqi1, WEI Yansong1
Received:2025-08-20
Online:2026-09-08
Published:2026-09-17
Supported by:CLC Number:
ZHANG Xiaonan, MA Zhichao, LIU An, HUANG Yuan, MIN Xuehong, LIU Mei, XIE Zhengqi, WEI Yansong. Determination of 33 non-steroidal anti-inflammatory drug residues in horse urine by QuEChERS-ultra performance liquid chromatography-tandem mass spectrometry[J]. Chinese Journal of Chromatography, 2026, 44(9): 1028-1037.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chrom-china.com/EN/10.3724/SP.J.1123.2025.08014
| Compound | tR/min | Parent ions (m/z) | Product ions (m/z) | Fragmentors/V | Collision energies/eV |
|---|---|---|---|---|---|
| Fenspiride (芬司匹利) | 1.94 | 261.2 | 105.1*, 77.1 | 127 | 30, 60 |
| Cinchophen (辛可芬) | 6.47 | 250.1 | 128.0*, 116.0 | 150 | 40, 40 |
| Piroxicam (吡罗昔康) | 5.19 | 332.1 | 95.1*, 78.1 | 110 | 18, 60 |
| Niflumic acid (尼氟灭酸) | 9.63 | 283.1 | 265.1*, 245.1 | 150 | 20, 40 |
| Propyphenazone (异丙安替比林) | 5.19 | 231.1 | 56.0*, 189.1 | 150 | 40, 20 |
| Meclofenamic acid (甲氯灭酸) | 10.77 | 296.0 | 278.1, 243.1* | 90 | 11, 30 |
| Salicylamide (水杨酰胺) | 3.30 | 138.0 | 121.1*, 65.0 | 100 | 15, 30 |
| Apazone (阿扎丙宗) | 4.65 | 301.2 | 189.2*, 145.2 | 110 | 26, 56 |
| Ketorolac (酮咯酸) | 5.75 | 256.1 | 105.1*, 77.1 | 120 | 19, 52 |
| Benoxaprofen (苯恶洛芬) | 10.36 | 302.1 | 256.1*, 270.0 | 150 | 40, 40 |
| Ketoprofen (酮洛芬) | 6.47 | 255.1 | 77.1, 209.2* | 120 | 52, 11 |
| Tiaprofenic acid (噻洛芬酸) | 6.16 | 261.1 | 105.1*, 77.0 | 150 | 20, 40 |
| Fenbufen (芬布芬) | 7.18 | 255.1 | 237.1, 181.2* | 90 | 7, 26 |
| Acemetacin (阿西美辛) | 9.38 | 416.1 | 139.1*, 111.1 | 120 | 26, 60 |
| Indomethacin (吲哚美辛) | 9.48 | 358.1 | 139.1*, 111.1 | 110 | 19, 56 |
| Indoibuprofen (吲哚布洛芬) | 5.76 | 282.1 | 236.1*, 77.1 | 130 | 23, 60 |
| Tolfenamic acid (托灭酸) | 12.06 | 262.1 | 244.1*, 209.2 | 100 | 15, 30 |
| Diclofenac (双氯芬酸) | 9.35 | 296.0 | 214.1*, 215.1 | 90 | 38, 19 |
| Rofecoxib (洛非考昔) | 4.50 | 315.1 | 269.1, 189.1* | 120 | 23, 60 |
| Celecoxib (塞来昔布) | 8.68 | 382.1 | 362.1*, 282.1 | 150 | 20, 40 |
| Etoricoxib (依托考昔) | 4.47 | 359.1 | 280.1*, 279.1 | 150 | 40, 40 |
| Oxaprozin (奥沙普嗪) | 8.70 | 294.1 | 103.2*, 276.2 | 120 | 34, 15 |
| Etodolac (依托度酸) | 9.19 | 288.2 | 172.2*, 143.2 | 80 | 11, 45 |
| Carprofen (卡洛芬) | 9.23 | 274.1 | 228.1, 193.0* | 110 | 15, 35 |
| Mefenamic acid (甲灭酸) | 11.27 | 242.1 | 224.2*, 209.2 | 100 | 15, 34 |
| Meloxicam (美洛昔康) | 6.33 | 352.0 | 115.1*, 73.0 | 110 | 19, 60 |
| Deracoxib (地拉考昔) | 6.24 | 398.1 | 378.1*, 283.1 | 140 | 30, 41 |
| Suprofen (舒洛芬) | 5.73 | 261.1 | 111.1*, 177.2 | 100 | 22, 19 |
| Eltenac (依尔替酸) | 8.75 | 302.0 | 221.1*, 220.1 | 100 | 23, 41 |
| Antipyrine (安替比林) | 3.20 | 189.1 | 56.0*, 77.1 | 130 | 37, 45 |
| Lornoxicam (氯诺昔康) | 5.37 | 372.0 | 121.1, 78.1* | 123 | 22, 60 |
| Naproxen (萘普生) | 6.96 | 231.1 | 185.2*, 170.2 | 97 | 15, 30 |
| Flufenamic acid (氟芬那酸) | 11.08 | 282.1, 280.1 | 264.1, 236.2* | 100, 110 | 11, 19 |
Table 1 Retention times, parent ions, product ions, fragmentors and collision energies of the 33 non-steroidal anti-inflammatory drugs (NSAIDs)
| Compound | tR/min | Parent ions (m/z) | Product ions (m/z) | Fragmentors/V | Collision energies/eV |
|---|---|---|---|---|---|
| Fenspiride (芬司匹利) | 1.94 | 261.2 | 105.1*, 77.1 | 127 | 30, 60 |
| Cinchophen (辛可芬) | 6.47 | 250.1 | 128.0*, 116.0 | 150 | 40, 40 |
| Piroxicam (吡罗昔康) | 5.19 | 332.1 | 95.1*, 78.1 | 110 | 18, 60 |
| Niflumic acid (尼氟灭酸) | 9.63 | 283.1 | 265.1*, 245.1 | 150 | 20, 40 |
| Propyphenazone (异丙安替比林) | 5.19 | 231.1 | 56.0*, 189.1 | 150 | 40, 20 |
| Meclofenamic acid (甲氯灭酸) | 10.77 | 296.0 | 278.1, 243.1* | 90 | 11, 30 |
| Salicylamide (水杨酰胺) | 3.30 | 138.0 | 121.1*, 65.0 | 100 | 15, 30 |
| Apazone (阿扎丙宗) | 4.65 | 301.2 | 189.2*, 145.2 | 110 | 26, 56 |
| Ketorolac (酮咯酸) | 5.75 | 256.1 | 105.1*, 77.1 | 120 | 19, 52 |
| Benoxaprofen (苯恶洛芬) | 10.36 | 302.1 | 256.1*, 270.0 | 150 | 40, 40 |
| Ketoprofen (酮洛芬) | 6.47 | 255.1 | 77.1, 209.2* | 120 | 52, 11 |
| Tiaprofenic acid (噻洛芬酸) | 6.16 | 261.1 | 105.1*, 77.0 | 150 | 20, 40 |
| Fenbufen (芬布芬) | 7.18 | 255.1 | 237.1, 181.2* | 90 | 7, 26 |
| Acemetacin (阿西美辛) | 9.38 | 416.1 | 139.1*, 111.1 | 120 | 26, 60 |
| Indomethacin (吲哚美辛) | 9.48 | 358.1 | 139.1*, 111.1 | 110 | 19, 56 |
| Indoibuprofen (吲哚布洛芬) | 5.76 | 282.1 | 236.1*, 77.1 | 130 | 23, 60 |
| Tolfenamic acid (托灭酸) | 12.06 | 262.1 | 244.1*, 209.2 | 100 | 15, 30 |
| Diclofenac (双氯芬酸) | 9.35 | 296.0 | 214.1*, 215.1 | 90 | 38, 19 |
| Rofecoxib (洛非考昔) | 4.50 | 315.1 | 269.1, 189.1* | 120 | 23, 60 |
| Celecoxib (塞来昔布) | 8.68 | 382.1 | 362.1*, 282.1 | 150 | 20, 40 |
| Etoricoxib (依托考昔) | 4.47 | 359.1 | 280.1*, 279.1 | 150 | 40, 40 |
| Oxaprozin (奥沙普嗪) | 8.70 | 294.1 | 103.2*, 276.2 | 120 | 34, 15 |
| Etodolac (依托度酸) | 9.19 | 288.2 | 172.2*, 143.2 | 80 | 11, 45 |
| Carprofen (卡洛芬) | 9.23 | 274.1 | 228.1, 193.0* | 110 | 15, 35 |
| Mefenamic acid (甲灭酸) | 11.27 | 242.1 | 224.2*, 209.2 | 100 | 15, 34 |
| Meloxicam (美洛昔康) | 6.33 | 352.0 | 115.1*, 73.0 | 110 | 19, 60 |
| Deracoxib (地拉考昔) | 6.24 | 398.1 | 378.1*, 283.1 | 140 | 30, 41 |
| Suprofen (舒洛芬) | 5.73 | 261.1 | 111.1*, 177.2 | 100 | 22, 19 |
| Eltenac (依尔替酸) | 8.75 | 302.0 | 221.1*, 220.1 | 100 | 23, 41 |
| Antipyrine (安替比林) | 3.20 | 189.1 | 56.0*, 77.1 | 130 | 37, 45 |
| Lornoxicam (氯诺昔康) | 5.37 | 372.0 | 121.1, 78.1* | 123 | 22, 60 |
| Naproxen (萘普生) | 6.96 | 231.1 | 185.2*, 170.2 | 97 | 15, 30 |
| Flufenamic acid (氟芬那酸) | 11.08 | 282.1, 280.1 | 264.1, 236.2* | 100, 110 | 11, 19 |
Fig. 1 Effects of (a) extraction solvent, (b) salt, (c) adsorbent and (d) extraction time on the extraction efficiencies of the 33 NSAIDs (n=3)S1: acetonitrile; S2: 1% formic acid acetonitrile; S3: ethyl acetate; S4: 1% formic acid ethyl acetate; S5: ethyl acetate-acetonitrile (1∶3, V/V); S6: ethyl acetate-acetonitrile (3∶1, V/V); S7: ethyl acetate-acetonitrile-dichloromethane (1∶2∶1, V/V/V).
| Level | A(Acetonitrile/mL) | B(Anhydrous MgSO4/mg) | C(C18/mg) | D(PSA/mg) |
|---|---|---|---|---|
| 1 | 3 | 300 | 20 | 30 |
| 2 | 4 | 400 | 30 | 40 |
| 3 | 5 | 500 | 40 | 50 |
Table 2 Factors and levels for the orthogonal experiment
| Level | A(Acetonitrile/mL) | B(Anhydrous MgSO4/mg) | C(C18/mg) | D(PSA/mg) |
|---|---|---|---|---|
| 1 | 3 | 300 | 20 | 30 |
| 2 | 4 | 400 | 30 | 40 |
| 3 | 5 | 500 | 40 | 50 |
| No. | Columns | Averagerecovery/% | |||
|---|---|---|---|---|---|
| A | B | C | D | ||
| 1 | 1 | 1 | 1 | 1 | 73.2 |
| 2 | 1 | 2 | 2 | 2 | 77.1 |
| 3 | 1 | 3 | 3 | 3 | 75.4 |
| 4 | 2 | 1 | 2 | 3 | 77.0 |
| 5 | 2 | 2 | 3 | 1 | 76.8 |
| 6 | 2 | 3 | 1 | 2 | 76.9 |
| 7 | 3 | 1 | 3 | 2 | 81.0 |
| 8 | 3 | 2 | 1 | 3 | 77.0 |
| 9 | 3 | 3 | 2 | 1 | 78.3 |
| K1 | 225.6 | 231.3 | 227.1 | 228.3 | |
| K2 | 230.7 | 231.0 | 232.5 | 234.9 | |
| K3 | 236.4 | 230.7 | 233.4 | 229.5 | |
| k1 | 75.2 | 77.1 | 75.7 | 76.1 | |
| k2 | 76.9 | 77.0 | 77.5 | 78.3 | |
| k3 | 78.8 | 76.9 | 77.8 | 76.5 | |
| R | 3.6 | 0.2 | 2.1 | 2.2 | |
| Order | A>D>C>B | ||||
| Optimal level | A3 | B1 | C3 | D2 | |
Table 3 Results of orthogonal experiments and range analysis
| No. | Columns | Averagerecovery/% | |||
|---|---|---|---|---|---|
| A | B | C | D | ||
| 1 | 1 | 1 | 1 | 1 | 73.2 |
| 2 | 1 | 2 | 2 | 2 | 77.1 |
| 3 | 1 | 3 | 3 | 3 | 75.4 |
| 4 | 2 | 1 | 2 | 3 | 77.0 |
| 5 | 2 | 2 | 3 | 1 | 76.8 |
| 6 | 2 | 3 | 1 | 2 | 76.9 |
| 7 | 3 | 1 | 3 | 2 | 81.0 |
| 8 | 3 | 2 | 1 | 3 | 77.0 |
| 9 | 3 | 3 | 2 | 1 | 78.3 |
| K1 | 225.6 | 231.3 | 227.1 | 228.3 | |
| K2 | 230.7 | 231.0 | 232.5 | 234.9 | |
| K3 | 236.4 | 230.7 | 233.4 | 229.5 | |
| k1 | 75.2 | 77.1 | 75.7 | 76.1 | |
| k2 | 76.9 | 77.0 | 77.5 | 78.3 | |
| k3 | 78.8 | 76.9 | 77.8 | 76.5 | |
| R | 3.6 | 0.2 | 2.1 | 2.2 | |
| Order | A>D>C>B | ||||
| Optimal level | A3 | B1 | C3 | D2 | |
| Compound | R2 | LOD/ (μg/L) | LOQ/ (μg/L) | LOQ | 20 μg/L | 200 μg/L | ME/% | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Recovery/% | RSD/% | Recovery/% | RSD/% | Recovery/% | RSD/% | |||||
| Fenspiride | 0.9995 | 0.1 | 1.1 | 75.2 | 7.2 | 103.5 | 6.7 | 92.8 | 5.9 | -84.9 |
| Cinchophen | 0.9997 | 0.1 | 1.1 | 96.5 | 4.3 | 97.7 | 7.4 | 95.6 | 4.6 | -31.8 |
| Piroxicam | 0.9983 | 0.1 | 1.0 | 78.2 | 7.5 | 99.2 | 6.8 | 91.3 | 5.6 | -12.4 |
| Niflumic acid | 0.9997 | 0.5 | 1.0 | 98.2 | 4.9 | 99.2 | 7.1 | 95.6 | 5.5 | -14.1 |
| Propyphenazone | 0.9995 | 0.1 | 1.1 | 85.4 | 7.2 | 92.3 | 8.0 | 88.3 | 7.6 | -13.9 |
| Meclofenamic acid | 0.9998 | 0.5 | 0.9 | 76.5 | 11.7 | 102.4 | 6.1 | 99.0 | 5.3 | -10.7 |
| Salicylamide | 0.9994 | 0.1 | 5.4 | 75.3 | 7.1 | 87.2 | 5.4 | 89.2 | 5.0 | -26.9 |
| Apazone | 0.9976 | 0.1 | 1.0 | 71.0 | 4.5 | 78.4 | 7.33 | 75.9 | 3.3 | 14.4 |
| Ketorolac | 0.9998 | 0.1 | 1.0 | 107.7 | 3.2 | 103.6 | 8.0 | 93.8 | 5.2 | -25.2 |
| Benoxaprofen | 0.9997 | 0.1 | 0.9 | 91.6 | 9.9 | 98.0 | 6.2 | 96.6 | 5.1 | -10.6 |
| Ketoprofen | 0.9986 | 0.5 | 1.1 | 93.3 | 13.3 | 95.4 | 9.5 | 92.0 | 3.4 | -5.8 |
| Tiaprofenic Acid | 0.9995 | 0.1 | 1.0 | 118.3 | 6.5 | 100.2 | 7.8 | 90.6 | 5.6 | -14.8 |
| Fenbufen | 0.9999 | 0.5 | 1.0 | 116.6 | 8.8 | 99.6 | 8.6 | 95.2 | 6.1 | -12.7 |
| Acemetacin | 0.9994 | 0.5 | 1.0 | 123.8 | 4.4 | 100.0 | 7.2 | 100.3 | 6.0 | 4.77 |
| Indomethacin | 0.9997 | 0.1 | 4.8 | 78.3 | 11.3 | 102.9 | 9.3 | 94.5 | 5.3 | 26.9 |
| Indoibuprofen | 0.9999 | 0.5 | 1.0 | 93.4 | 14.8 | 104.8 | 6.8 | 92.4 | 7.0 | 31.6 |
| Tolfenamic acid | 0.9996 | 0.5 | 1.0 | 76.8 | 12.9 | 106.6 | 7.0 | 103.1 | 5.9 | -13.3 |
| Diclofenac | 0.9998 | 0.1 | 1.1 | 105.3 | 5.7 | 101.5 | 8.1 | 95.0 | 3.7 | -10.6 |
| Rofecoxib | 0.9987 | 1.0 | 5.3 | 80.2 | 7.1 | 94.1 | 10.4 | 83.1 | 4.6 | -71.6 |
| Celecoxib | 0.9999 | 1.0 | 5.4 | 91.6 | 11.0 | 101.8 | 8.6 | 92.8 | 7.2 | -36.6 |
| Etoricoxib | 0.9988 | 0.1 | 0.9 | 101.4 | 9.5 | 95.0 | 8.2 | 95.5 | 3.7 | -16.7 |
| Oxaprozin | 0.9999 | 0.1 | 1.0 | 101.4 | 4.7 | 98.1 | 7.0 | 94.4 | 6.5 | -5.8 |
| Etodolac | 0.9995 | 0.1 | 1.1 | 92.5 | 5.8 | 91.7 | 7.5 | 91.4 | 1.9 | -2.2 |
| Carprofen | 0.9996 | 0.5 | 1.1 | 95.5 | 14.1 | 101.4 | 6.3 | 92.7 | 5.9 | -14.7 |
| Mefenamic acid | 0.9998 | 0.1 | 1.1 | 95.4 | 10.7 | 102.5 | 7.0 | 101.4 | 5.9 | -17.2 |
| Meloxicam | 0.9999 | 0.1 | 1.0 | 116.3 | 3.7 | 93.9 | 6.6 | 92.0 | 4.9 | -10.4 |
| Deracoxib | 0.9997 | 0.1 | 0.9 | 73.1 | 8.0 | 97.4 | 8.6 | 91.5 | 4.8 | -42.8 |
| Suprofen | 0.9999 | 0.5 | 1.1 | 119.4 | 9.9 | 99.4 | 5.7 | 91.9 | 5.3 | -27.1 |
| Eltenac | 0.9997 | 0.5 | 1.0 | 102.6 | 7.1 | 98.0 | 7.6 | 96.3 | 4.4 | -9.47 |
| Antipyrine | 0.9990 | 0.1 | 1.0 | 93.5 | 5.1 | 104.3 | 6.8 | 96.6 | 5.0 | -20.5 |
| Lornoxicam | 0.9998 | 0.5 | 5.2 | 117.4 | 5.2 | 104.6 | 7.8 | 93.8 | 5.6 | -13.4 |
| Naproxen | 0.9997 | 0.5 | 1.1 | 70.8 | 9.4 | 98.8 | 7.1 | 93.7 | 5.1 | -29.0 |
| Flufenamic acid | 0.9965 | 0.5 | 5.2 | 89.8 | 4.2 | 93.7 | 7.2 | 83.8 | 6.2 | 15.7 |
Table 4 Coefficients of determination (R2), recoveries, RSDs, LODs, LOQs and matrix effects (MEs) of the 33 NSAIDs in horse urine (n=6)
| Compound | R2 | LOD/ (μg/L) | LOQ/ (μg/L) | LOQ | 20 μg/L | 200 μg/L | ME/% | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Recovery/% | RSD/% | Recovery/% | RSD/% | Recovery/% | RSD/% | |||||
| Fenspiride | 0.9995 | 0.1 | 1.1 | 75.2 | 7.2 | 103.5 | 6.7 | 92.8 | 5.9 | -84.9 |
| Cinchophen | 0.9997 | 0.1 | 1.1 | 96.5 | 4.3 | 97.7 | 7.4 | 95.6 | 4.6 | -31.8 |
| Piroxicam | 0.9983 | 0.1 | 1.0 | 78.2 | 7.5 | 99.2 | 6.8 | 91.3 | 5.6 | -12.4 |
| Niflumic acid | 0.9997 | 0.5 | 1.0 | 98.2 | 4.9 | 99.2 | 7.1 | 95.6 | 5.5 | -14.1 |
| Propyphenazone | 0.9995 | 0.1 | 1.1 | 85.4 | 7.2 | 92.3 | 8.0 | 88.3 | 7.6 | -13.9 |
| Meclofenamic acid | 0.9998 | 0.5 | 0.9 | 76.5 | 11.7 | 102.4 | 6.1 | 99.0 | 5.3 | -10.7 |
| Salicylamide | 0.9994 | 0.1 | 5.4 | 75.3 | 7.1 | 87.2 | 5.4 | 89.2 | 5.0 | -26.9 |
| Apazone | 0.9976 | 0.1 | 1.0 | 71.0 | 4.5 | 78.4 | 7.33 | 75.9 | 3.3 | 14.4 |
| Ketorolac | 0.9998 | 0.1 | 1.0 | 107.7 | 3.2 | 103.6 | 8.0 | 93.8 | 5.2 | -25.2 |
| Benoxaprofen | 0.9997 | 0.1 | 0.9 | 91.6 | 9.9 | 98.0 | 6.2 | 96.6 | 5.1 | -10.6 |
| Ketoprofen | 0.9986 | 0.5 | 1.1 | 93.3 | 13.3 | 95.4 | 9.5 | 92.0 | 3.4 | -5.8 |
| Tiaprofenic Acid | 0.9995 | 0.1 | 1.0 | 118.3 | 6.5 | 100.2 | 7.8 | 90.6 | 5.6 | -14.8 |
| Fenbufen | 0.9999 | 0.5 | 1.0 | 116.6 | 8.8 | 99.6 | 8.6 | 95.2 | 6.1 | -12.7 |
| Acemetacin | 0.9994 | 0.5 | 1.0 | 123.8 | 4.4 | 100.0 | 7.2 | 100.3 | 6.0 | 4.77 |
| Indomethacin | 0.9997 | 0.1 | 4.8 | 78.3 | 11.3 | 102.9 | 9.3 | 94.5 | 5.3 | 26.9 |
| Indoibuprofen | 0.9999 | 0.5 | 1.0 | 93.4 | 14.8 | 104.8 | 6.8 | 92.4 | 7.0 | 31.6 |
| Tolfenamic acid | 0.9996 | 0.5 | 1.0 | 76.8 | 12.9 | 106.6 | 7.0 | 103.1 | 5.9 | -13.3 |
| Diclofenac | 0.9998 | 0.1 | 1.1 | 105.3 | 5.7 | 101.5 | 8.1 | 95.0 | 3.7 | -10.6 |
| Rofecoxib | 0.9987 | 1.0 | 5.3 | 80.2 | 7.1 | 94.1 | 10.4 | 83.1 | 4.6 | -71.6 |
| Celecoxib | 0.9999 | 1.0 | 5.4 | 91.6 | 11.0 | 101.8 | 8.6 | 92.8 | 7.2 | -36.6 |
| Etoricoxib | 0.9988 | 0.1 | 0.9 | 101.4 | 9.5 | 95.0 | 8.2 | 95.5 | 3.7 | -16.7 |
| Oxaprozin | 0.9999 | 0.1 | 1.0 | 101.4 | 4.7 | 98.1 | 7.0 | 94.4 | 6.5 | -5.8 |
| Etodolac | 0.9995 | 0.1 | 1.1 | 92.5 | 5.8 | 91.7 | 7.5 | 91.4 | 1.9 | -2.2 |
| Carprofen | 0.9996 | 0.5 | 1.1 | 95.5 | 14.1 | 101.4 | 6.3 | 92.7 | 5.9 | -14.7 |
| Mefenamic acid | 0.9998 | 0.1 | 1.1 | 95.4 | 10.7 | 102.5 | 7.0 | 101.4 | 5.9 | -17.2 |
| Meloxicam | 0.9999 | 0.1 | 1.0 | 116.3 | 3.7 | 93.9 | 6.6 | 92.0 | 4.9 | -10.4 |
| Deracoxib | 0.9997 | 0.1 | 0.9 | 73.1 | 8.0 | 97.4 | 8.6 | 91.5 | 4.8 | -42.8 |
| Suprofen | 0.9999 | 0.5 | 1.1 | 119.4 | 9.9 | 99.4 | 5.7 | 91.9 | 5.3 | -27.1 |
| Eltenac | 0.9997 | 0.5 | 1.0 | 102.6 | 7.1 | 98.0 | 7.6 | 96.3 | 4.4 | -9.47 |
| Antipyrine | 0.9990 | 0.1 | 1.0 | 93.5 | 5.1 | 104.3 | 6.8 | 96.6 | 5.0 | -20.5 |
| Lornoxicam | 0.9998 | 0.5 | 5.2 | 117.4 | 5.2 | 104.6 | 7.8 | 93.8 | 5.6 | -13.4 |
| Naproxen | 0.9997 | 0.5 | 1.1 | 70.8 | 9.4 | 98.8 | 7.1 | 93.7 | 5.1 | -29.0 |
| Flufenamic acid | 0.9965 | 0.5 | 5.2 | 89.8 | 4.2 | 93.7 | 7.2 | 83.8 | 6.2 | 15.7 |
| Sample pretreatment method | Matrix | Detection | Number of compounds | Linear range/ (μg/L) | LOQ/(μg/L) | Ref. |
|---|---|---|---|---|---|---|
| LLE | equine plasma | LC-MS | 16 | 5.0-200 | 1.0-5.0 | [ |
| SPE | equine urine | GC-MS | 9 | 25-375 | 53.0-267.2 | [ |
| MSB-LPME | human serum | LC-MS | 4 | - | 0.83-3.16 | [ |
| SPMTE | human urine | LC-UV | 4 | 10-10000 | 11-31 | [ |
| μSPE | whole blood | LC-UV | 3 | 50-2000 | 50-75 | [ |
| MISPE | equine plasma | LC-UV | 7 | 80-250000 | 10-80 | [ |
| QuEChERS | equine urine | LC-MS | 33 | 0.9-220 | 0.9-5.4 | this study |
Table 5 Comparison of this method with other methods
| Sample pretreatment method | Matrix | Detection | Number of compounds | Linear range/ (μg/L) | LOQ/(μg/L) | Ref. |
|---|---|---|---|---|---|---|
| LLE | equine plasma | LC-MS | 16 | 5.0-200 | 1.0-5.0 | [ |
| SPE | equine urine | GC-MS | 9 | 25-375 | 53.0-267.2 | [ |
| MSB-LPME | human serum | LC-MS | 4 | - | 0.83-3.16 | [ |
| SPMTE | human urine | LC-UV | 4 | 10-10000 | 11-31 | [ |
| μSPE | whole blood | LC-UV | 3 | 50-2000 | 50-75 | [ |
| MISPE | equine plasma | LC-UV | 7 | 80-250000 | 10-80 | [ |
| QuEChERS | equine urine | LC-MS | 33 | 0.9-220 | 0.9-5.4 | this study |
| Sample No. | Place of birth | NSAID residues/(μg/L) | ||
|---|---|---|---|---|
| Ketorolac | Lornoxicam | Naproxen | ||
| 1 | Belgium | 1.05 | <LOQ | 6.87 |
| 2 | Holland | 1.10 | <LOQ | - |
| 3 | Belgium | <LOQ | <LOQ | - |
| 4 | Belgium | <LOQ | <LOQ | - |
| 5 | Germany | 1.01 | <LOQ | - |
| 6 | Holland | - | <LOQ | - |
| 7 | Belgium | - | - | <LOQ |
| 8 | Belgium | <LOQ | <LOQ | - |
| 9 | Belgium | - | <LOQ | - |
| 10 | Belgium | - | <LOQ | - |
Table 6 Test results of the 10 horse urine samples (n=3)
| Sample No. | Place of birth | NSAID residues/(μg/L) | ||
|---|---|---|---|---|
| Ketorolac | Lornoxicam | Naproxen | ||
| 1 | Belgium | 1.05 | <LOQ | 6.87 |
| 2 | Holland | 1.10 | <LOQ | - |
| 3 | Belgium | <LOQ | <LOQ | - |
| 4 | Belgium | <LOQ | <LOQ | - |
| 5 | Germany | 1.01 | <LOQ | - |
| 6 | Holland | - | <LOQ | - |
| 7 | Belgium | - | - | <LOQ |
| 8 | Belgium | <LOQ | <LOQ | - |
| 9 | Belgium | - | <LOQ | - |
| 10 | Belgium | - | <LOQ | - |
|
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||